An observational study in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-23.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.
This study uses a literature review, qualitative (focus groups) and quantitative methods (discrete-choice experiment, DCE) to determine renal cell carcinoma (RCC) participants and oncologists' preferences. In this clinical trial, the study team will develop a survey consisting of comparisons of hypothetical treatment profiles (scenarios). Scenarios are presented to participants, and each participant chooses the most preferable.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 105 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with diagnosis of Renal Cell Carcinoma (RCC) from a total of eight to eleven hospitals (6-8 located in Spain and 2-3 in Portugal) and oncologists with expertise in renal cancer from Spain and Portugal will participate in the study.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Oncologists from Spain and Portugal will be identified by the promoter and invited to participate in the study in accordance with the inclusion criteria described below.
Participants with a diagnosis of RCC will be identified and recruited by the Principal Investigators of the study, taking into account the inclusion criteria described below.
Exclusion Criteria:
Participants with renal cell carcinoma (RCC) treated with nivolumab
Oncologists with expertise in renal cancer from Spain and Portugal
Utility: Renal cell carcinoma (RCC) participants' preferences
Utility (preference score) derived for a treatment alternative choice (scenario)
Time frame: At Baseline
Utility: Oncologists' preferences
Utility (preference score) derived for a treatment alternative choice (scenario)
Time frame: At Baseline
Distribution of socio-demographic characteristics of Renal cell carcinoma (RCC) participants: Age
Mean age, defined as the difference in time between date of birth and baseline visit
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: Time since RCC diagnosis
Mean time to diagnosis, defined as the differences in time between date of diagnosis and baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Place of residence
Place of residence, defined as Province of residence categories at baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Gender
Gender, defined as Gender categories at baseline visit, defined as female and male
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Economic status (income)
Economic status, defined as Euros per month
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Education level
Education level, defined as education level categories at baseline visit, defined as primary education, secondary education, university education, third-level studies (masters, doctorate, etc.)
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Working situation
Working situation, defined as working situation categories at baseline visit defined as full-time employed, part-time employed, self-employed, employed but on temporary sick leave due to RCC, permanent sick leave due to RCC, student, unemployed, retired, housework
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Transport to the hospital: means, duration and cost
Time frame: At Baseline
Distribution of socio-demographic characteristics of RCC participants: Other costs derived from the visit to the hospital (parking, meals...)
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: American Joint Committee on Cancer (AJCC) Staging
AJCC staging, defined as AJCC disease staging categories at baseline visit defined as Localized disease: Stages I and II; or advanced disease: Stages III and IV
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: Charlson index
Charlson index, defined as Mean score according to Charlson comorbidity index
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: Karnofsky Performance Scale Index
Karnofsky Performance Scale Index categories at baseline visit, defined as (0-100%); Lower score representing worst functional impairment
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: Current drug treatment (if applicable)
Current drug treatment, defined as drug treatment categories at baseline visit
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: Identification of previous pharmacological treatments received by the participant for the treatment of RCC
Previous drug treatment, defined as drug treatment categories at baseline visit
Time frame: At Baseline
Distribution of clinical characteristics of RCC participants: Description of previous pharmacological treatments received by the participant for the treatment of RCC
Previous drug treatment, defined as drug treatment categories at baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Gender
Gender, defined as Gender categories at baseline visit, defined as female and male
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Age
Mean age, defined as the difference in time between date of birth and baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Province where employed
Province where employed, defined as Province categories at baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Years of experience in RCC
Years of experience in RCC, defined as Mean time of experience in RCC at baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Years of experience in oncology
Years of experience in oncology, defined as Mean time of experience in oncology at baseline visit
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Number of participants with RCC seen per year
Number of participants with RCC seen per year, defined as Mean time of participants with RCC seen per year
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Other types of cancer treated
Other types of cancer treated, defined as other cancers treated
Time frame: At Baseline
Distribution of socio-demographic characteristics of oncologists: Level/ classification of hospital where employed
Hospital level or classification categories at baseline visit, defined as first, second, third, and fourth level
Time frame: At Baseline
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb